About Pricing FAQs Blog

Loading clinical trials...

Clareo Health Find Clinical Trials →

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Portland | 4,842 Studies Near You | Clareo Health

Clinical Trials LocationsPortland

Clinical Trials in Portland

Discover 4,842 clinical trials near Portland, Oregon. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 861-880 of 4,842 trials

COMPLETEDNA< 1 mile

Clinical Validation Study of the Eximis CS (Contained Segmentation) System

NCT06572163

The purpose of this study is to evaluate device safety and effectiveness of the Eximis CS System.

Laparoscopic Gynecological Surgical Procedures

Eximis Surgical23 participantsStarted Sep 2024

Celebration, Florida, United States • Idaho Falls, Idaho, United States • Brooklyn, New York, United States +1 more locations

ACTIVE_NOT_RECRUITINGPHASE2< 1 mile

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema

NCT06116916

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.

Diabetic Macular Edema (DME)

Kyowa Kirin Co., Ltd.150 participantsStarted Jan 2024

Mesa, Arizona, United States • Tucson, Arizona, United States • Arcadia, California, United States +84 more locations

Find Trials by Condition in Portland

Breast Cancerin Portland Lung Cancerin Portland Prostate Cancerin Portland Colorectal Cancerin Portland Melanomain Portland Leukemiain Portland Lymphomain Portland Pancreatic Cancerin Portland Ovarian Cancerin Portland Brain Cancerin Portland Diabetes

Data from ClinicalTrials.govTerms

COMPLETEDPHASE2< 1 mile

Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

NCT03694002

This randomized phase II trial studies how well carboplatin and paclitaxel with or without ramucirumab work in treating patients with thymic cancer that has spread to other places in the body, has come back, or cannot be removed by surgery. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as ramucirumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known if giving carboplatin and paclitaxel with or without ramucirumab will work better in treating patients with thymic cancer.

Locally Advanced Thymic CarcinomaMetastatic Thymic CarcinomaRecurrent Thymic Carcinoma+1 more

SWOG Cancer Research Network21 participantsStarted Mar 2019

Anchorage, Alaska, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +251 more locations

RECRUITINGNA< 1 mile

Evaluate the Safety and Effectiveness of the Polymotion Hip Resurfacing (PHR) System Compared to Total Hip Arthroplasty

NCT06792539

The goal of this clinical trial is to evaluate the safety and effectiveness of the Polymotion Hip Resurfacing (PHR) System compared to total hip arthroplasty, for adults who require hip resurfacing arthroplasty due to 1) non-inflammatory arthritis (degenerative joint disease) such as osteoarthritis, traumatic arthritis, or 2) mild dysplasia/developmental dislocation of the hip (DDH) up to Crowe Grade 1.

Osteoarthritis of the HipDegenerative Joint Disease of HipDysplasia; Hip

JointMedica Inc.238 participantsStarted Jan 2025

Tampa, Florida, United States • Chicago, Illinois, United States • Baltimore, Maryland, United States +7 more locations

COMPLETEDNA< 1 mile

Influence of Yogic Breathwork on CSF Circulation

NCT03858309

The purpose of this research study is to determine the influence of yoga breathing practices on cerebrospinal fluid (CSF) circulation, and to find out primarily if a regular practice of 8-week yoga breathing would enhance CSF circulation as well as if the intervention would improve participant's quality of life, quality of sleep, and reduce existing stress. Participants will be randomized into two arms for different breathing practices.

CSF Circulation

Oregon Health and Science University26 participantsStarted Jul 2019

Portland, Oregon, United States

COMPLETEDPHASE2< 1 mile

Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy

NCT02203695

The primary hypothesis of this study is that outcomes for patients with biochemically recurrent prostate cancer following radical prostatectomy will be improved by the addition of enzalutamide for 6-months compared to standard-of-care salvage radiation therapy to allow for further study in the definitive phase III setting. This study builds on the prior success of high-dose bicalutamide (for 24 months) when combined with salvage external radiation therapy (XRT), while using a newer more potent anti-androgen for a shorter duration of time (6 months) in an effort to minimize adverse effects.

Adenocarcinoma of the Prostate

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins86 participantsStarted Mar 2015

Washington D.C., District of Columbia, United States • Chicago, Illinois, United States • Lafayette, Indiana, United States +6 more locations

COMPLETEDPHASE1< 1 mile

Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia

NCT03900949

This phase I study hopes to explore how safe and tolerable is the combination of gemtuzumab ozogamicin (GO) and midostaurin, with the standard induction therapy (cytarabine and daunorubicin) in patients with newly diagnosed FLT-3 mutated Acute Myeloid Leukemia (AML). GO is FDA approved for the treatment of adults with newly diagnosed CD33 positive AML and used in combination with chemotherapy, cytarabine and daunorubicin. Midostaurin is FDA approved for use with cytarabine and daunorubicin in patients with FLT3-mutated AML. By combining standard induction therapy with GO and midostaurin, our aim is to investigate a novel approach to treating patients with newly diagnosed FLT3-mutated AML.

Acute Myeloid Leukemia

Uma Borate21 participantsStarted Mar 2019

Columbus, Ohio, United States • Portland, Oregon, United States

RECRUITINGNA145 miles

Combining a Smartphone App With Medications to Manage Heavy Drinking

NCT06303778

One in 10 Veterans have an alcohol use disorder. However, few Veterans receive evidenced-based psychosocial interventions or medications to treat alcohol use disorder. Barriers to receiving these treatments include long wait times, stigma, and long distances from treatment facilities. Even fewer Veterans receive psychosocial and medication interventions together, despite clinical practice guidelines recommending both and evidence of better outcomes. Expanding access to these treatments in primary care is a VA priority but delivering psychosocial interventions is difficult in this setting, and medication is often the only option. Smartphone apps that deliver alcohol interventions may improve drinking outcomes and ensure Veterans can receive both treatments in primary care. This study will determine whether medications and an app for alcohol use problems offered to Veterans in primary care results in improved drinking outcomes, compared to Veterans receiving medications only. Study data will inform how to spread the app across the VA nationally.

Alcohol Use Disorder (AUD)

VA Office of Research and Development330 participantsStarted Nov 2024

Phoenix, Arizona, United States • Fayetteville, Arkansas, United States • Washington D.C., District of Columbia, United States +12 more locations

ACTIVE_NOT_RECRUITING145 miles

OCS Heart Perfusion Post-Approval Registry

NCT05047068

The objective of this post-approval registry is to provide additional real-world evidence of the performance of the OCS Heart System to preserve DBD and DCD donor hearts.

TransMedics350 participantsStarted Sep 2021

Los Angeles, California, United States • Palo Alto, California, United States • San Francisco, California, United States +24 more locations

RECRUITINGPHASE4145 miles

Individualizing Treatment for Asthma in Primary Care (Full Study)

NCT07052942

While asthma therapy is becoming more individualized based on asthma phenotypes, more research is needed to tailor newer therapies to individuals. Inhaled corticosteroid (ICS) medications are the foundation of care for all individuals with persistent asthma. But ICS use is not without possible long term side effects. This study will compare two currently available approaches to reduce AEX in primary care patients: (1) use of inhaled corticosteroids (ICS) as part of rescue therapy, also known as MART (Maintenance And Reliever Therapy) or PARTICS (Patient Activated Reliever Trigger Inhaled Corticosteriods) therapy - either of these therapies will be called Rescue-Inhaled Corticosteroids or R-ICS pronounced "Ricks," and (2) use of azithromycin (AZ) as a preventive therapy. These treatments will be studied both individually and in combination.

AsthmaAsthma AttackAsthma Exacerbations

DARTNet Institute3,200 participantsStarted Aug 2025

Aurora, Colorado, United States • Aurora, Colorado, United States • Orlando, Florida, United States +10 more locations

RECRUITINGPHASE1145 miles

A Study of XMT-1660 in Participants With Solid Tumors

NCT05377996

A Study of XMT-1660 in Solid Tumors

Triple Negative Breast CancerBreast CancerEndometrial Cancer+4 more

Mersana Therapeutics319 participantsStarted Aug 2022

Phoenix, Arizona, United States • Orange, California, United States • San Francisco, California, United States +23 more locations

COMPLETEDPHASE2145 miles

A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

NCT05809934

A Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 given by subcutaneous injection in adult participants with non-cirrhotic non-alcoholic steatohepatitis with fibrosis and who are carriers of the PNPLA3 148M Risk Allele

Nonalcoholic Steatohepatitis

AstraZeneca220 participantsStarted Mar 2023

Chandler, Arizona, United States • Peoria, Arizona, United States • Surprise, Arizona, United States +161 more locations

ACTIVE_NOT_RECRUITINGPHASE2145 miles

Phase 2b Study of GSK4532990 in Adults With NASH

NCT05583344

The purpose of this study is to measure improvements in liver fibrosis and inflammation with GSK4532990 compared with placebo in participants with NASH and advanced fibrosis on biopsy (F3 or F4). The study duration will be up to 76 weeks including the screening period. The treatment duration will be up to 52 weeks.

Nonalcoholic Fatty Liver DiseaseNon-alcoholic Fatty Liver Disease

GlaxoSmithKline284 participantsStarted Jan 2023

Homewood, Alabama, United States • Chandler, Arizona, United States • Chandler, Arizona, United States +167 more locations

ACTIVE_NOT_RECRUITINGPHASE2177 miles

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

NCT05456685

IMGN853-0420 is a multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 prior line of platinum-based chemotherapy.

High Grade Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer

AbbVie125 participantsStarted Sep 2022

Tucson, Arizona, United States • Fresno, California, United States • Fullerton, California, United States +66 more locations

RECRUITINGPHASE3341 miles

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

NCT06008093

The purpose of the study is to assess the efficacy of durvalumab plus tremelimumab in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy in metastatic NSCLC patients with non-squamous histology who have mutations and/or co-mutations in STK11, KEAP1, or KRAS.

Carcinoma, Non-Small-Cell Lung

AstraZeneca280 participantsStarted Apr 2024

Birmingham, Alabama, United States • Anchorage, Alaska, United States • Chandler, Arizona, United States +102 more locations

COMPLETEDPHASE1535 miles

Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)

NCT03010176

The purpose of this study is to identify a maximum tolerated dose (MTD) or maximum administered dose (MAD) of ulevostinag alone and of ulevostinag in combination with pembrolizumab in participants with advanced/metastatic solid tumors or lymphomas in Part 1, and to evaluate the safety and efficacy of ulevostinag via intratumoral (IT) injection in combination with pembrolizumab in selected solid tumors in Part 2. Ulevostinag will be administered IT; pembrolizumab (pembro) will be administered via intravenous (IV) infusion. In Part 1, participants will be allocated to one of three treatment arms: ulevostinag monotherapy (cutaneous/subcutaneous \[cut/subcut\] lesions), ulevostinag +pembro (cut/subcut lesions), or ulevostinag +pembro (visceral lesions). In Part 2, participants with head and neck squamous cell carcinoma (HNSCC) who are anti-programmed cell death-protein 1 or anti-programmed cell death-ligand 1 (anti-PD-1/PD-L1) refractory or with anti-PD-1/PD-L1 treatment (TrT)-naïve triple-negative breast cancer (TNBC) or with anti-PD-1/PD-L1 TrT-naïve solid tumors with liver metastases/lesions will receive ulevostinag via IT injection at the preliminary Recommended Phase 2 Dose (RP2D) determined in Part 1 PLUS pembrolizumab via IV infusion for up 35 cycles (up approximately 2 years).

Solid TumorsLymphoma

Merck Sharp & Dohme LLC156 participantsStarted Feb 2017

Birmingham, Alabama, United States • San Francisco, California, United States • San Francisco, California, United States +16 more locations

COMPLETEDPHASE2535 miles

Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)

NCT04220866

The purpose of this study is to assess the efficacy and safety of intratumoral (IT) ulevostinag PLUS pembrolizumab (MK-3475) compared to pembrolizumab alone as a first line treatment of adults with metastatic or unresectable, recurrent head and neck squamous cell carcinoma (HNSCC). The primary study hypotheses are that IT ulevostinag in combination with pembrolizumab results in a superior Objective Response Rate (ORR), per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), compared to pembrolizumab alone: 1. In participants with a tumor that has a programmed cell death-ligand 1 (PD-L1) Combined Positive Scoring (CPS) ≥ 1, and 2. In participants with a tumor that has a PD-L1 CPS ≥ 20.

Head and Neck Squamous Cell Carcinoma (HNSCC)

Merck Sharp & Dohme LLC18 participantsStarted Mar 2020

Los Angeles, California, United States • San Francisco, California, United States • Detroit, Michigan, United States +31 more locations

RECRUITINGPHASE1/PHASE2535 miles

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

NCT04665206

This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.

Solid Tumor, AdultMesotheliomaNSCLC

Vivace Therapeutics, Inc336 participantsStarted Mar 2021

San Francisco, California, United States • Chicago, Illinois, United States • Boston, Massachusetts, United States +9 more locations

RECRUITING535 miles

Stryker's Surgeon iD Mandible Reconstruction Plates: A Retrospective Post Market Follow Up

NCT07221916

A retrospective post market follow up to confirm safety and performance of Stryker's Surgeon iD Plates (SMRP) medical device. The study is performed to confirm the product's performance and safety by systematically collecting clinical data on its use.

Mandible FractureMandibular Reconstruction

Stryker Craniomaxillofacial50 participantsStarted Dec 2024

San Francisco, California, United States • Zwickau, Germany

ACTIVE_NOT_RECRUITINGNA559 miles

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).

NCT01586910

The purpose of the study is to investigate the safety and efficacy of transcatheter aortic valve implantation (TAVI) in patients with severe, symptomatic Aortic Stenosis (AS) at intermediate surgical risk by randomizing patients to either Surgical Aortic Valve Replacement (SAVR) or TAVI with the Medtronic CoreValve® System. Single Arm: The purpose of this trial is to evaluate the safety and effectiveness of transcatheter aortic valve implementation (TAVI) in patients with severe symptomatic Aortic Stenosis (AS) at intermediate surgical risk with TAVI. This is a non-randomized phase of the pivotal clinical trial.

Severe Aortic Stenosis

Medtronic Cardiovascular1,746 participantsStarted Apr 2012

Phoenix, Arizona, United States • Hollywood, California, United States • La Jolla, California, United States +83 more locations

PreviousPage 44 of 243Next

in Portland

Heart Diseasein Portland